CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 6% – Here’s What Happened

CytoMed Therapeutics Limited (NASDAQ:GDTC) traded down 6% on Friday . The company traded as low as $0.93 and last traded at $0.9301. Approximately 26,738 shares were traded during mid-day trading, a decline of 87% from the average session volume of 201,908 shares. The stock had previously closed at $0.9894.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, CytoMed Therapeutics currently has a consensus rating of “Sell”.

CytoMed Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.17 and a current ratio of 5.17. The firm has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.02.

Insider Buying and Selling at CytoMed Therapeutics

In related news, Director Chee Kong Choo purchased 112,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $1.15 per share, with a total value of $128,800.00. Following the purchase, the director owned 430,324 shares of the company’s stock, valued at $494,872.60. This trade represents a 35.18% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.